| 摘要 |
The new strain Lactobacillus pentosus CECT 7504 is provided. The strain presents as key advantages: a high survival to the antimicrobial factors found in vaginal fluid, factors that are often increased in a subset of patients with candidiasis, and that could be very harmful to many probiotics; the capacity to inhibit Candida albicans and Candida glabrata, thus displaying a broader spectrum activity to help manage Candida infections such as vulvovaginal candidiasis; the capacity to survive against high concentrations of antimycotic agents typically used to manage Candida infections, thus allowing its co-administration; and an improved capacity to acidify vaginal fluid, thus displaying a high potential to help manage bacterial vaginosis. Therefore, the strain and products comprising it are useful in the prevention and/or treatment of candidiasis (oral, intestinal and vaginal) and of bacterial vaginosis. |
